Identified gene mutations impact on the severity of a type of hematologic cancer

August 04, 2020

The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).

This study, published in the prestigious scientific journal Nature Medicine, has been conducted by researchers from the Memorial Sloan Kettering in the USA, involving 25 research centers in 12 countries and has been supervised by the international working group for the prognosis of MDS, whose aim is to develop new international guidelines for the diagnosis and treatment of this disease. This is a preliminary result in order to define a prognostic score based on molecular changes.

Considered the "guardian of the genome," TP53 is the most commonly mutated gene in cancer. The normal function of TP53 is to detect DNA damages and prevent cells from passing this damage to daughter cells. When TP53 is mutated, the protein resulting from this gene (called p53) can no longer perform this protective function and a cancer may be the result. In most cancers, TP53 mutations are associated with a worse prognosis, such as disease relapse, poor response to treatments and shorter survival.

TP53 exists in duplicate in each of our cells, just like all other genes: one copy from our mother and one copy from our father. Until now, it was not clear whether a mutation of a single copy of TP53 was enough to cause a worse prognosis of the disease, or whether mutations in both copies were necessary.

This study has confirmed for the first time that having the two mutated copies of the TP53 gene is associated with worse results for myelodysplastic syndromes (MDS), a group of blood cancers whose common characteristic is that the stem cells in the bone marrow, in charge of manufacturing all the blood cells, have a defect that makes them produce abnormal cells, unable to perform their usual functions, and in a lower quantity.

Dr. Solé, leader of the Josep Carreras Institute's Myelodysplastic Syndromes group, member of the Spanish Myelodysplastic Syndromes Group (GESMD) and member of the international working group for the prognosis of MDS, explains: "From the Josep Carreras Institute we have actively participated by providing more than a hundred samples from patients with the diagnosis of MDS, in the comparative analysis of cytogenetic (karyotype) results versus those obtained by mass sequencing, and in the final discussion of the findings obtained. The results of this study will allow a great advance in the diagnosis and treatment of myelodysplastic syndromes. Current guidelines do not consider genomic data, such as the mutational status of TP53 and other genes to assess prognosis in patients with MDS or to determine appropriate treatment for this disease. However, studies like this show that we should include this information to improve the diagnosis and treatment of patients".

By using new computational methods in a serie of 4,444 patients with MDS, the researchers found that a third of the patients with TP53 mutations had only a mutated copy of this gene. These patients had similar results to patients who did not have a TP53 mutation, that is to say good response to treatment, low rates of disease progression and long-term survival. However, two-thirds of patients had both mutated copies of TP53 and these patients had worse results, including resistance to treatment, rapid disease progression, and short-term survival.

In fact, the researchers found that the TP53 mutation status (0, 1, or 2 mutated copies of the gene), was the most important variable in predicting the clinical course of the disease.

Given the frequency of TP53 mutations in cancer, these results also advocate to examine the impact of one or two mutations on other types of cancer, both hematologic and solid tumors, and reveal the need of clinical trials specifically designed with these molecular differences.
-end-


Josep Carreras Leukaemia Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.